No Data
No Data
Zhejiang Wolwo Bio-pharmaceutical (300357.SZ) joint venture company developed a clinical trial summary report for "Inhalable Aescin A Solution"
Zhejiang Wolwo Bio-pharmaceutical (300357.SZ) released an announcement that its joint venture company, Shanghai Kaiyi Pharmaceutical Technology Co., Ltd. (referred to as...
Are Investors Undervaluing Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) By 49%?
Zhejiang Wolwo Bio-Pharmaceutical: Summary of Half-Year Report in 2024.
Zhejiang Wolwo Bio-Pharmaceutical: Half-year report for the year 2024.
Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ): The net income in the first half of the year was 0.149 billion yuan, a year-on-year increase of 0.42%.
GeLongHui August 22 | Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) released its semi-annual report for 2024, with a total operating income of 0.429 billion yuan during the reporting period, an 11.12% year-on-year increase; net income attributable to shareholders of the listed company was 0.149 billion yuan, a 0.42% year-on-year increase; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.142 billion yuan, a 0.69% year-on-year decrease; basic earnings per share were 0.2850 yuan.
Zhejiang Wolwo Bio-pharmaceutical (300357.SZ): The first subject of the phase II clinical trial of the Dermatitis Diagnostic Patch 01 has been enrolled.
On August 12, Gelunhui reported that Zhejiang Wolwo Bio-pharmaceutical Co., Ltd. (stock code: 300357.SZ) announced that the "Pityriasis Diagnosing Patch 01 Patch" developed by Zhejiang Wolwo Bio-pharmaceutical Science and Technology Co., Ltd. has completed the first subject grouping in a clinical study of the diagnostic effect and safety of Pityriasis Diagnosing Patch 01 Patch in Chinese patients with allergic contact dermatitis at the Huashan Hospital affiliated to Fudan University. It has officially entered the clinical trial. The "Pityriasis Diagnosing Patch 01 Patch" is applied to the patch test to diagnose allergic contact dermatitis caused by three metal allergens: nickel, chromium, and cobalt. Allergic contact dermatitis belongs to type IV (delayed type) allergy.
No Data
No Data